Learn More
Apexbio Technology LLC Dacomitinib (PF299804, PF299) 1110813-31-4 10mM (in 1mL DMSO)

Supplier: Apexbio Technology LLC A83195.1

Dacomitinib (PF299804 CAS 1110813-31-4) is an irreversible pan-HER small-molecule inhibitor that targets the epidermal growth factor receptor (EGFR/ErbB-1) ERBB2 (HER2) and ERBB4 (HER4) It acts by covalently binding EGFR family tyrosine kinases inhibiting downstream signaling through phospho-HER family proteins AKT and ERK Dacomitinib shows activity in vitro inducing G0/G1 cell cycle arrest and apoptosis and suppresses proliferation in trastuzumab- or lapatinib-resistant HER2-amplified breast cancer cell lines In vivo studies demonstrate antitumor effects in EGFR-mutant (e g T790M) gefitinib-resistant lung cancer xenografts making it relevant for non-small cell lung cancer research
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.